Bavarian Nordic modtager kontrakt på EUR 65 mio. vedrørende levering af koppevacciner til strategisk lager i EU
29 avr. 2024 15h30 HE
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 29. april 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en kontrakt til en værdi af EUR 65 mio. vedrørende levering af koppevacciner til det...
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
29 avr. 2024 15h30 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic reserve...
Bavarian Nordic påbegynder løbende registreringsansøgning for chikungunya-vaccine til de amerikanske sundhedsmyndigheder
29 avr. 2024 09h03 HE
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 29. april 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har påbegyndt en løbende indsendelse til de amerikanske sundhedsmyndigheder, U.S. Food and Drug...
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
29 avr. 2024 09h03 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
22 avr. 2024 12h00 HE
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 22. april 2024 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
22 avr. 2024 12h00 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding...
Beslutninger på den ordinære generalforsamling 2024 i Bavarian Nordic A/S
16 avr. 2024 12h20 HE
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 16. april 2024 – Bavarian Nordic A/S (OMX: BAVA) har i dag afholdt ordinær generalforsamling med følgende resultater: Årsrapporten for 2023 blev godkendt. Bestyrelsens...
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
16 avr. 2024 12h20 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2023 was adopted. The Board of Directors’...
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
02 avr. 2024 02h00 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant...
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
02 avr. 2024 02h00 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant...